All In Biotech

Drug Trial Radar · NCT06507839

Study to Assess the Safety, Tolerability, Pharmacokinetic of Thrv-1268

A First-in-Human, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study To Assess the Safety, Tolerability, Pharmacokinetics, and Food Effect of Thrv-1268 in Healthy Adult Subjects

Last checked: Nov 20, 2026Latest source record: May 13, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

56

Actual

Start

May 15, 2024

Primary completion

Nov 1, 2024

Study completion Nov 1, 2024

Sponsor

Lead sponsor
Thryv TherapeuticsIndustry
Sponsor type
Industry
First posted
Jul 18, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Other
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a single-center, randomized, double-blind, placebo-controlled study to be conducted in 2 parts: single ascending dose (SAD) incorporating a food effect arm and multiple ascending dose (MAD). Potential participants for each part will undergo screening procedures within 28 days of enrollment.

Conditions

  • Atrial Fibrillation

Interventions

  • THRV-1268Drug

    THRV-1268 a serum glucocorticoid regulated kinase 1 (SGK-1) inhibitor

  • PlaceboOther

    Matching placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and Tolerability: Number of Participants with Adverse EventsTime frame: SAD: Day 7; Food Effect: Day 15; MAD: Day 16

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Altasciences

    Montreal, Quebec, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.